Article
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.
Nature medicine - 1 Feb 2026
Brastianos Priscilla K, Dooley Katharine, Geyer Susan, Gerstner Elizabeth R, Kaufmann Timothy J, Iafrate A John, Martinez-Lage Maria, Milhem Mohammed, Welch Mary Roberta, Kaley Thomas J, Drappatz Jan, Chan Amy, Kumthekar Priya, Matsuoka Carlos Kamiya, Strowd Roy E, Cohen Adam L, Jaeckle Kurt, Robell Lindsay, Magge Rajiv S, Nam Joo Yeon, Blondin Nicholas, Shaikh Nawal, Rabinowitz Ian, Thomas Alissa A, Piccioni David E, Brown Paul, Kaluziak Stefan, Codd Elizabeth, Cahill Daniel P, Santagata Sandro, Barker Frederick G, Galanis Evanthia
Abstract excerpt
Systemic treatments are limited for patients with meningiomas that have progressed after surgery or radiation. Loss of NF2 and CDKN2A/CDKN2B is common in higher-grade meningiomas and promotes progression in preclinical models. We evaluated the efficacy of abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, as one arm of the Alliance umbrella trial A071401, a genomically driven phase 2 study in recurrent and...
Topics
Join the communities discussing this publication.